SCHEMBL3344200

SCHEMBL3344200

Cc1cc2nc(CSc3cccc(Cl)c3)cc(O)n2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
GAA P10253 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
GRM5 P41594 1/20 0.40
MAOB P27338 2/20 0.39
MAOA P21397 1/20 0.39
DHFR P00374 1/20 0.38
POLB P06746 1/20 0.38
KDM4E B2RXH2 2/20 0.37
CXCR2 P25025 1/20 0.37
RECQL P46063 1/20 0.37
ALOX5 P09917 1/20 0.36
DPP4 P27487 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3339153 0.86 MAOB (0.39) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL3339372 0.86 PTGDR2 (0.40) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL3338701 0.82 CXCR2 (0.40) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL3341624 0.76 CXCR2 (0.50) RAB9AMAOBCXCR2
SCHEMBL3338709 0.75 KDM1A (0.38) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL3338499 0.75 CXCR2 (0.39) NPC1RAB9ASMN1; SMN2KMT2ATDP1
SCHEMBL956425 0.72 KDM4E (0.39) NPC1SMN1; SMN2MEN1KMT2AHTT
SCHEMBL958613 0.72 MRGPRX4 (0.50) NPC1RAB9ASMN1; SMN2DPP4
SCHEMBL3365665 0.69 KDM4E (0.55) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL3337864 0.68 CXCR2 (0.49) CXCR2DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100152205-A1 CXCR2 INHIBITORS NOVARTIS AG 2010-06-17 US claimed
US-20100152205-A1 CXCR2 INHIBITORS NOVARTIS AG 2010-06-17 US disclosed
EP-2094697-A1 5-SULFANYLMETHYL-PYRAZOLO [1,5-A]PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS Novartis AG (CH) 2009-09-02 EP disclosed
WO-2008062026-A1 5-SULFANYLMETHYL-PYRAZOLO [1,5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS NOVARTIS AG (CH) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152205-A1 CXCR2 INHIBITORS CXCR2, CXCR1, CXCR3 MAPT 4670/4885NPC1 787/4885RAB9A 1737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.